NHS England's Wegovy expansion is a major cardiovascular-prevention decision, but the policy will be judged in local prescribing and follow-up systems rather than in the national announcement. NICE published final guidance on May 7, 2026, recommending semaglutide for reducing major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity.
NHS England said around 1.2 million people in England could be eligible. That is an estimate of the population meeting the criteria, not a promise that 1.2 million prescriptions will be issued at once. NICE's resource model instead forecasts a phased start, with 31,000 people beginning treatment in year one and 103,100 receiving semaglutide by year three.
The Eligibility Is Narrower Than the Hype
The new route does not mean anyone seeking weight loss can get Wegovy from the NHS. Eligible adults must have established cardiovascular disease, defined as a previous heart attack, previous ischaemic or haemorrhagic stroke, or symptomatic peripheral arterial disease, and a BMI of at least 27. A clinician must also consider semaglutide the most suitable option.
Clear eligibility language matters because public confusion around GLP-1 drugs is already high. Wegovy, Ozempic and Mounjaro do not have identical indications, access routes or evidence for preventing another cardiovascular event. This recommendation concerns weekly Wegovy injections as an addition to standard prevention, not general access to a weight-loss product.
Eligibility Is Not Immediate Access
NICE requires the NHS in England to fund the treatment within 90 days of final guidance. That obligation does not eliminate the work needed to deliver it. Services must identify eligible patients, confirm cardiovascular history and BMI, review existing medicines, explain risks and benefits, arrange prescribing and monitor treatment.
The practical risk is a gap between national eligibility and local readiness. Patients may hear that Wegovy is available, then find that their local pathway is still being organized. NICE's own uptake forecast makes the distinction explicit: an eligible population of about 1.21 million sits beside a much smaller number expected to receive treatment during the first three years.
The Delivery Setting Still Needs Decisions
The final NICE guidance does not specify one setting for semaglutide. Its resource-impact report lists NHS hospital trusts and primary care as providers and integrated care boards as commissioners. That leaves local systems to decide how work is divided between GPs, specialists and other services.
Primary care capacity will still matter because many eligible patients are already managed there for blood pressure, cholesterol and other secondary-prevention needs. But the policy should not quietly transfer a complex new workload to GP practices without staff, prescribing support and a clear route for specialist advice. A national funding duty needs an operational pathway.
Equity Is the Public-Health Test
Cardiovascular disease and obesity do not fall evenly across England. Deprived communities often carry higher risk and have less spare capacity to navigate complex care. If access becomes easiest for patients who are confident, digitally literate, persistent and already well connected to the health system, the rollout will miss part of its public-health purpose.
Equity requires active case finding, clear referral routes and local monitoring of who is actually receiving treatment. A patchy rollout would turn a national prevention policy into another postcode lottery. The NHS has to avoid a system where private buyers move quickly while high-risk public patients wait behind local bottlenecks.
The 20% Trial Result Needs the Right Frame
Among 17,604 participants in the SELECT trial, those assigned semaglutide alongside existing cardiovascular care were 20% less likely than the placebo group to experience the composite outcome of cardiovascular death, non-fatal heart attack or non-fatal stroke. That is a relative reduction in a combined trial endpoint, not a guarantee that an individual patient will avoid another event.
NICE recommends the drug alongside a reduced-calorie diet, increased physical activity and standard cardiovascular care. Semaglutide does not replace statins, blood-pressure treatment, smoking cessation or clinical follow-up. The recommendation adds one option to secondary prevention; it does not turn one injection into a complete heart-protection plan.
The Drug Cannot Carry Prevention Alone
Semaglutide can be an effective add-on for selected high-risk patients, but it cannot repair the food environment, poverty, stress, sedentary work, air quality, housing insecurity or unequal care access that help drive cardiovascular disease. If politicians treat the rollout as a shortcut around those harder determinants, the NHS will be left medicating a problem it cannot fully prescribe away.
Wegovy gives the NHS a useful prevention tool and a delivery test at the same time. The evidence supports offering it to the defined high-risk group. The 1.2 million figure does not prove that the system can reach that group safely or fairly. The outcome will depend less on the size of the announcement than on whether commissioners build a pathway that can find the right patients and support them after the prescription is written.